FRAMINGHAM, Mass., April 10, 2015 /PRNewswire/ -- HeartWare
International, Inc. (NASDAQ: HTWR), a leading innovator of less
invasive, miniaturized circulatory support technologies that are
revolutionizing the treatment of advanced heart failure, today
announced it will webcast two events at the 35th
International Society for Heart and Lung Transplantation (ISHLT)
Annual Meeting and Scientific Sessions in Nice, France on Thursday, April 16, 2015.
Investor Breakout Session
HeartWare CEO Doug Godshall will host an investor breakout
session at 3:00 p.m. local time
(9:00 a.m. U.S. Eastern Time) on
April 16, 2015. A live webcast
of HeartWare's investor meeting will be available to the public at
http://edge.media-server.com/m/p/efpikrgn and through the investor
section of the company's website at www.heartware.com. A
replay of the webcast will be available through the above weblink
shortly following completion of the call.
HeartWare ISHLT Symposium
HeartWare will host a lunch
symposium titled, "Deeper Dive into HeartWare Clinical and
Real-World Results," on Thursday, April 16,
2015 from 12:45 p.m. to 2:15
p.m. local time (6:45 a.m. to 8:15
a.m. U.S. Eastern Time). The meeting will be held in
the Clio/Thalie room at the Acropolis Congress Center.
Clinicians from the U.S. and Europe will highlight clinical and commercial
experience with the HeartWare System, including discussions of the
oral presentations detailed below.
An audio feed of the symposium will be available to the public
via webcast at http://edge.media-server.com/m/p/fwekfebu and
through the investor section of the company's website at
www.heartware.com. A replay of the webcast will be available
through the above weblink shortly following completion of the
call.
Select Oral Presentations at ISHLT on April 16 (all times local):
HeartWare HVAD for the Treatment of Patients with Advanced
Heart Failure Ineligible for Cardiac Transplantation: Results of
the ENDURANCE Destination Therapy Trial (Pagani)
Thursday, April 16 at 9:50 am
Long Term Support of Patients Receiving an LVAD for Advanced
Heart Failure: A Subgroup Analysis of the Registry to Evaluate the
HeartWare® Left Ventricular Assist System (The REVOLVE
Registry) (Schmitto)
Thursday, April 16 at 11:00 am
The HeartWare HVAD Pump in Clinical Practice - Results from
1,035 Patients Analyzed in a Retrospective European Multi-Center
Study (Krabatsch)
Thursday, April 16; at 11:45 am
Neurological Events in Patients Bridged with Long-Term
Mechanical Circulatory Support: A Device Specific Comparative
Analysis (Maltais)
Thursday, April 16; at 4:30 pm
About HeartWare International
HeartWare International
develops and manufactures miniaturized implantable heart pumps, or
ventricular assist devices, to treat Class IIIB / IV patients
suffering from advanced heart failure. The
HeartWare® Ventricular Assist System features the
HVAD® pump, a small full-support circulatory assist
device designed to be implanted next to the heart, avoiding the
abdominal surgery generally required to implant competing
devices. The HeartWare System is approved in the United States for the intended use as a
bridge to cardiac transplantation in patients who are at risk of
death from refractory end-stage left ventricular heart failure, has
received CE Marking in the European Union and has been used to
treat patients in 41 countries. The device is also currently
the subject of a U.S. clinical trial for destination therapy.
For additional information, please visit the Company's website at
www.heartware.com.
For additional information:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartware.com
Phone: +1 508 739 0864
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/heartware-announces-webcasts-at-the-35th-international-society-for-heart-and-lung-transplantation-annual-meeting-300064348.html
SOURCE HeartWare International, Inc.